Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1receptor positive allosteric modulators
AssigneeEli Lilly and Company
InventorsJunliang Hao, Richard D. Johnston, Gregory Lawrence Lackner, Erik J. Hembre, Kjell A. Svensson
Life of this patent
Estimating the term…
Abstract
The invention provides certain (phenyl)-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one related compounds of formula I as D1 positive allosteric modulators (PAMs), and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula I, to treat certain symptoms of dopaminergic CNS disorders including Parkinson's disease, Schizophrenia, ADHD or Alzheimer's disease.
Claims14
A compound of the formula:
- wherein:
- R1 is
- R2 is —F or —Cl;
- R3 is —F or —Cl;
- and
- R4 is —H or —F;
- provided that when R1 is
- then R4 is —F.
A method of treating a dopaminergic CNS disorder comprising administering to a patient in need thereof an effective amount of a compound which is 2-(2-chloro-6-fluoro-phenyl)-1-[(1S,3R)-6-fluoro-3-(hydroxymethyl)-5-(3-hydroxy-3-methyl-butyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone wherein the dopaminergic CNS disorder is Parkinson's disease or Alzheimer's disease.
Dependencies are inferred from the claim text.